In the clinic, dual blockade of CTLA-4 and PD-1 can achieve a more effective anti-tumour immune response in melanoma as both the CTLA-4 and PD-1 axes inhibit T cell activation and function using non-redundant mechanisms [47]. The gene discussed is CTLA4; the disease is neoplasm.